# Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

> **NCT00680485** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 96 (—)

## Conditions studied

- Bacterial Infection
- Infections, Bacterial

## Interventions

- **DRUG:** GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

## Key facts

- **NCT ID:** NCT00680485
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 96 (—)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680485, "Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00680485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*